RSS Feeds
Remission of Hepatitis B Virus-Related Vasculitis with Lamivudine
- Takuya Sawabe, MD, PhD;
- Takeshi Uenotsuchi, MD;
- Shinichi Imafuku, MD;
- Hiroshi Kohno, MD;
- Junichi Arima, MD, PhD; and
- Takahiko Horiuchi, MD, PhD
- From Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima 730-8619, and Kyushu University Graduate School of Medical Sciences, Fukuoka 812-8582, Japan.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Background: Lamivudine is a nucleoside analogue approved for treating chronic hepatitis B (1, 2), and one case report has suggested that it may also be effective for treating vasculitis associated with hepatitis B virus (HBV) infection (3). We describe a patient …
This 100-word excerpt has been provided in the absence of an abstract.
